Key result
Intravenous oxindanac caused reversible inhibition of platelet cyclo-oxygenase in calves, with inhibition of serum TxB2 predictable from total plasma drug concentration.
No takes yet. Share an insight, caveat, or question.
Supports concentration-dependent platelet inhibition modeling in calves; leaves open translation to clinical antiplatelet therapy.
Jonathan N. King (1994) studied this question. Oxindanac was evaluated on Pharmacokinetics and inhibition of serum TxB2. Intravenous oxindanac caused reversible inhibition of platelet cyclo-oxygenase in calves, with inhibition of serum TxB2 predictable from total plasma drug concentration.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: